TABLE 3.
Grade of fatty liver during VSL#3® treatment at baseline and after 3 months.
| Placebo |
VSL#3® |
|||
| Baseline |
3 months |
Baseline |
3 months |
|
| N | 30 | 30 | 30 | 30 |
| Grade 1, n (%) | 16 (53.3) | 14 (46.7) | 19 (63.3) | 5 (16.7)°** |
| Grade 2, n (%) | 10 (33.3) | 10 (33.3) | 8 (26.7) | 5 (16.7)*^ |
| Grade 3, n (%) | 4 (13.3) | 4 (13.3) | 3 (10.0) | 2 (6.7) |
Data are expressed as number or percentage. *p < 0.05 vs. baseline;°p < 0.01 vs. baseline; ∧p < 0.05 vs. placebo; **p < 0.01 vs. placebo.